Brain reserve contributes to distinguishing preclinical Alzheimer's stages 1 and 2

  1. Yildirim, Zerrin
  2. Delen, Firuze
  3. Berron, David
  4. Baumeister, Hannah
  5. Ziegler, Gabriel
  6. Schütze, Hartmut
  7. Glanz, Wenzel
  8. Dobisch, Laura
  9. Peters, Oliver
  10. Freiesleben, Silka Dawn ORCID logo
  11. Schneider, Luisa-Sophie
  12. Priller, Josef
  13. Spruth, Eike Jakob
  14. Schneider, Anja
  15. Fliessbach, Klaus
  16. Wiltfang, Jens
  17. Schott, Björn ORCID logo
  18. Meiberth, Dix
  19. Buerger, Katharina
  20. Janowitz, Daniel
  21. Perneczky, Robert
  22. Rauchmann, Boris-Stephan
  23. Teipel, Stefan
  24. Kilimann, Ingo
  25. Laske, Christoph
  26. Munk, Matthias H.
  27. Spottke, Annika
  28. Roy, Nina
  29. Heneka, Michael
  30. Brosseron, Frederic
  31. Wagner, Michael
  32. Roeske, Sandra
  33. Ramirez, Alfredo
  34. Ewers, Michael
  35. Dechent, Peter
  36. Hetzer, Stefan
  37. Scheffler, Klaus
  38. Kleineidam, Luca
  39. Wolfsgruber, Steffen
  40. Yakupov, Renat
  41. Schmid, Matthias
  42. Berger, Moritz
  43. Gurvit, Hakan
  44. Jessen, Frank
  45. Duzel, Emrah

Download
s13195-023-01187-9.pdf 955,95KB
WeightNameValue
1000 Titel
  • Brain reserve contributes to distinguishing preclinical Alzheimer's stages 1 and 2
1000 Autor/in
  1. Yildirim, Zerrin |
  2. Delen, Firuze |
  3. Berron, David |
  4. Baumeister, Hannah |
  5. Ziegler, Gabriel |
  6. Schütze, Hartmut |
  7. Glanz, Wenzel |
  8. Dobisch, Laura |
  9. Peters, Oliver |
  10. Freiesleben, Silka Dawn |
  11. Schneider, Luisa-Sophie |
  12. Priller, Josef |
  13. Spruth, Eike Jakob |
  14. Schneider, Anja |
  15. Fliessbach, Klaus |
  16. Wiltfang, Jens |
  17. Schott, Björn |
  18. Meiberth, Dix |
  19. Buerger, Katharina |
  20. Janowitz, Daniel |
  21. Perneczky, Robert |
  22. Rauchmann, Boris-Stephan |
  23. Teipel, Stefan |
  24. Kilimann, Ingo |
  25. Laske, Christoph |
  26. Munk, Matthias H. |
  27. Spottke, Annika |
  28. Roy, Nina |
  29. Heneka, Michael |
  30. Brosseron, Frederic |
  31. Wagner, Michael |
  32. Roeske, Sandra |
  33. Ramirez, Alfredo |
  34. Ewers, Michael |
  35. Dechent, Peter |
  36. Hetzer, Stefan |
  37. Scheffler, Klaus |
  38. Kleineidam, Luca |
  39. Wolfsgruber, Steffen |
  40. Yakupov, Renat |
  41. Schmid, Matthias |
  42. Berger, Moritz |
  43. Gurvit, Hakan |
  44. Jessen, Frank |
  45. Duzel, Emrah |
1000 Erscheinungsjahr 2023
1000 LeibnizOpen
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2023-02-28
1000 Erschienen in
1000 Quellenangabe
  • 15(1):43
1000 FRL-Sammlung
1000 Copyrightjahr
  • 2023
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s13195-023-01187-9 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972621/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • BACKGROUND: In preclinical Alzheimer's disease, it is unclear why some individuals with amyloid pathologic change are asymptomatic (stage 1), whereas others experience subjective cognitive decline (SCD, stage 2). Here, we examined the association of stage 1 vs. stage 2 with structural brain reserve in memory-related brain regions. METHODS: We tested whether the volumes of hippocampal subfields and parahippocampal regions were larger in individuals at stage 1 compared to asymptomatic amyloid-negative older adults (healthy controls, HCs). We also tested whether individuals with stage 2 would show the opposite pattern, namely smaller brain volumes than in amyloid-negative individuals with SCD. Participants with cerebrospinal fluid (CSF) biomarker data and bilateral volumetric MRI data from the observational, multi-centric DZNE-Longitudinal Cognitive Impairment and Dementia Study (DELCODE) study were included. The sample comprised 95 amyloid-negative and 26 amyloid-positive asymptomatic participants as well as 104 amyloid-negative and 47 amyloid-positive individuals with SCD. Volumes were based on high-resolution T2-weighted images and automatic segmentation with manual correction according to a recently established high-resolution segmentation protocol. RESULTS: In asymptomatic individuals, brain volumes of hippocampal subfields and of the parahippocampal cortex were numerically larger in stage 1 compared to HCs, whereas the opposite was the case in individuals with SCD. MANOVAs with volumes as dependent data and age, sex, years of education, and DELCODE site as covariates showed a significant interaction between diagnosis (asymptomatic versus SCD) and amyloid status (Aß42/40 negative versus positive) for hippocampal subfields. Post hoc paired comparisons taking into account the same covariates showed that dentate gyrus and CA1 volumes in SCD were significantly smaller in amyloid-positive than negative individuals. In contrast, CA1 volumes were significantly (p = 0.014) larger in stage 1 compared with HCs. CONCLUSIONS: These data indicate that HCs and stages 1 and 2 do not correspond to linear brain volume reduction. Instead, stage 1 is associated with larger than expected volumes of hippocampal subfields in the face of amyloid pathology. This indicates a brain reserve mechanism in stage 1 that enables individuals with amyloid pathologic change to be cognitively normal and asymptomatic without subjective cognitive decline.
1000 Sacherschließung
lokal Brain reserve
lokal Hippocampus
lokal Cerebrospinal fluid (CSF)
lokal Amyloid pathologic change
lokal Aß42/40
lokal Memory
lokal Alzheimer’s disease (AD)
lokal Medial temporal lobe
lokal Subjective cognitive decline (SCD)
lokal Magnetic resonance imaging (MRI)
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/WWlsZGlyaW0sIFplcnJpbg==|https://frl.publisso.de/adhoc/uri/RGVsZW4sIEZpcnV6ZQ==|https://frl.publisso.de/adhoc/uri/QmVycm9uLCBEYXZpZA==|https://frl.publisso.de/adhoc/uri/QmF1bWVpc3RlciwgSGFubmFo|https://frl.publisso.de/adhoc/uri/WmllZ2xlciwgR2FicmllbA==|https://frl.publisso.de/adhoc/uri/U2Now7x0emUsIEhhcnRtdXQ=|https://frl.publisso.de/adhoc/uri/R2xhbnosIFdlbnplbA==|https://frl.publisso.de/adhoc/uri/RG9iaXNjaCwgTGF1cmE=|https://frl.publisso.de/adhoc/uri/UGV0ZXJzLCBPbGl2ZXI=|https://orcid.org/0000-0002-2141-8671|https://frl.publisso.de/adhoc/uri/U2NobmVpZGVyLCBMdWlzYS1Tb3BoaWU=|https://frl.publisso.de/adhoc/uri/UHJpbGxlciwgSm9zZWY=|https://frl.publisso.de/adhoc/uri/U3BydXRoLCBFaWtlIEpha29i|https://frl.publisso.de/adhoc/uri/U2NobmVpZGVyLCBBbmph|https://frl.publisso.de/adhoc/uri/RmxpZXNzYmFjaCwgS2xhdXM=|https://frl.publisso.de/adhoc/uri/V2lsdGZhbmcsIEplbnM=|https://orcid.org/0000-0002-8237-4481|https://frl.publisso.de/adhoc/uri/TWVpYmVydGgsIERpeA==|https://frl.publisso.de/adhoc/uri/QnVlcmdlciwgS2F0aGFyaW5h|https://frl.publisso.de/adhoc/uri/SmFub3dpdHosIERhbmllbA==|https://frl.publisso.de/adhoc/uri/UGVybmVjemt5LCBSb2JlcnQ=|https://frl.publisso.de/adhoc/uri/UmF1Y2htYW5uLCBCb3Jpcy1TdGVwaGFu|https://frl.publisso.de/adhoc/uri/VGVpcGVsLCBTdGVmYW4=|https://frl.publisso.de/adhoc/uri/S2lsaW1hbm4sIEluZ28=|https://frl.publisso.de/adhoc/uri/TGFza2UsIENocmlzdG9waA==|https://frl.publisso.de/adhoc/uri/TXVuaywgTWF0dGhpYXMgSC4=|https://frl.publisso.de/adhoc/uri/U3BvdHRrZSwgQW5uaWth|https://frl.publisso.de/adhoc/uri/Um95LCBOaW5h|https://frl.publisso.de/adhoc/uri/SGVuZWthLCBNaWNoYWVs|https://frl.publisso.de/adhoc/uri/QnJvc3Nlcm9uLCBGcmVkZXJpYw==|https://frl.publisso.de/adhoc/uri/V2FnbmVyLCBNaWNoYWVs|https://frl.publisso.de/adhoc/uri/Um9lc2tlLCBTYW5kcmE=|https://frl.publisso.de/adhoc/uri/UmFtaXJleiwgQWxmcmVkbw==|https://frl.publisso.de/adhoc/uri/RXdlcnMsIE1pY2hhZWw=|https://frl.publisso.de/adhoc/uri/RGVjaGVudCwgUGV0ZXI=|https://frl.publisso.de/adhoc/uri/SGV0emVyLCBTdGVmYW4=|https://frl.publisso.de/adhoc/uri/U2NoZWZmbGVyLCBLbGF1cw==|https://frl.publisso.de/adhoc/uri/S2xlaW5laWRhbSwgTHVjYQ==|https://frl.publisso.de/adhoc/uri/V29sZnNncnViZXIsIFN0ZWZmZW4=|https://frl.publisso.de/adhoc/uri/WWFrdXBvdiwgUmVuYXQ=|https://frl.publisso.de/adhoc/uri/U2NobWlkLCBNYXR0aGlhcw==|https://frl.publisso.de/adhoc/uri/QmVyZ2VyLCBNb3JpdHo=|https://frl.publisso.de/adhoc/uri/R3Vydml0LCBIYWthbg==|https://frl.publisso.de/adhoc/uri/SmVzc2VuLCBGcmFuaw==|https://frl.publisso.de/adhoc/uri/RHV6ZWwsIEVtcmFo
1000 Label
1000 Förderer
  1. Projekt DEAL |
  2. Deutsches Zentrum für Neurodegenerative Erkrankungen |
  3. Deutsche Forschungsgemeinschaft |
  4. Türk Nöroloji Derneği |
1000 Fördernummer
  1. -
  2. -
  3. 42589994
  4. -
1000 Förderprogramm
  1. Open Access funding
  2. -
  3. -
  4. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Projekt DEAL |
    1000 Förderprogramm Open Access funding
    1000 Fördernummer -
  2. 1000 joinedFunding-child
    1000 Förderer Deutsches Zentrum für Neurodegenerative Erkrankungen |
    1000 Förderprogramm -
    1000 Fördernummer -
  3. 1000 joinedFunding-child
    1000 Förderer Deutsche Forschungsgemeinschaft |
    1000 Förderprogramm -
    1000 Fördernummer 42589994
  4. 1000 joinedFunding-child
    1000 Förderer Türk Nöroloji Derneği |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6475347.rdf
1000 Erstellt am 2024-04-24T13:50:00.499+0200
1000 Erstellt von 242
1000 beschreibt frl:6475347
1000 Bearbeitet von 317
1000 Zuletzt bearbeitet 2024-04-29T07:39:02.855+0200
1000 Objekt bearb. Mon Apr 29 07:37:54 CEST 2024
1000 Vgl. frl:6475347
1000 Oai Id
  1. oai:frl.publisso.de:frl:6475347 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source